TheraRadar
Data updated: May 26, 2026

POTIGA (ezogabine)

Trial Activity: Declining
CNS Approved 2011-06-10
Jump to: Indications Approvals Trials Competitors Safety Patents

Development Insights

James Murrough conducting 1 trials (33%)
5 indications explored (Moderate)
→ depressive disorder (1 trials)
→ anhedonia (1 trials)
→ amyotrophic lateral sclerosis (1 trials)
1
Indication
--
Phase 3 Trials
14
Years on Market

Details

Status
Discontinued
First Approved
2011-06-10
Routes
ORAL
Dosage Forms
TABLET

Companies

GSK
Active Ingredient: EZOGABINE

POTIGA Approval History

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
32 FDA actions from 2011 to 2016
May 2016 SUPPL
Label · Labeling
FDA Letter Label
Nov 2015 SUPPL
Update · REMS
FDA Letter
May 2015 SUPPL
Label · Labeling
FDA Letter Label

What POTIGA Treats

1 FDA approvals

Originally approved for its first indication in 2011 .

  • Other (1)
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT03043560 results posted GCO 16-0374 1R61MH111932-01 Ph 2 completed Study to Treat Major Depressive Disorder With a New Medication
NCT02450552 results posted 2014D002776 Ph 2 completed Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
NCT02149836 results posted GCO 14-0597 Ph 2 completed Study to Treat Major Depressive Disorder (MDD) With a New Medication
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

POTIGA FDA Label Details

Track POTIGA with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: NDA022345 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment